PHRX.CN down 33% to C$0.01 on 19 Feb 2026: what traders should watch

PHRX.CN stock plunged 33.33% to C$0.01 in market hours on 19 Feb 2026, making Pharmadrug Inc. (PHRX.CN) one of today’s top losers on the CNQ in Canada. The move followed heavy selling after the stock opened at C$0.015 and hit a day low of C$0.01, with 28,921 shares trading vs an average of 37,944. Traders should watch liquidity, short-term technical levels and the company’s weak fundamentals, which explain why volume and price action are driving the decline during regular market hours.

Price action and trading data for PHRX.CN stock

PHRX.CN stock closed at C$0.01, down C$0.005 or 33.33% from the previous close of C$0.015. Intraday range was C$0.01–C$0.015 with volume at 28,921 shares versus an average volume of 37,944, signaling lower-than-average liquidity. Market capitalization stands near C$1,082,344 and shares outstanding are 108,234,380, which magnifies price swings for small orders.

Fundamentals and valuation for PHRX.CN stock

Pharmadrug Inc. reports trailing EPS of -0.01 and a negative PE of -1.0, reflecting losses and no positive earnings. Book value per share is -0.01395 and shareholders equity per share is -0.01506, which points to negative net assets on a per-share basis. Enterprise value is C$2,566,315, giving EV/EBITDA of -26.88, underlining weak operating profitability and stretched valuation metrics for a microcap in the Healthcare sector.

Technical picture and short-term signals for PHRX.CN stock

Technical indicators show downside pressure: RSI 33.39 sits near oversold and ADX 51.66 signals a strong trend. The 50-day average is C$0.015 and the 200-day average is C$0.01275, both above the current price, which indicates a bearish bias. Bollinger upper band is C$0.02 and lower band C$0.01, so volatility is compressed around the current low price.

News, partnerships and risk drivers for PHRX.CN stock

Pharmadrug focuses on psychedelics, cannabis and naturally-derived medicines and lists collaborations with the University of Michigan and Johns Hopkins in research agreements that add scientific credibility. Short-term risk drivers include cash runway, small free cash flow per share (-0.00075) and thin liquidity, while opportunity hinges on clinical progress or commercial contracts in the EU medical cannabis market. For company details see the official site Pharmadrug Inc..

Analyst sentiment, rating and Meyka AI grade for PHRX.CN stock

Independent company ratings flagged a C- on 12 Feb 2026 with a Recommendation of Strong Sell driven by weak DCF and balance-sheet metrics. Meyka AI rates PHRX.CN with a score out of 100: 67.94 (Grade B) and suggests HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Forecasts and realistic price targets for PHRX.CN stock

Meyka AI’s forecast model projects a near-term price of C$0.01, in line with today’s close, implying 0.00% upside vs the current price of C$0.01. We set a conservative short-term price target range: bear C$0.005 (-50.00%), base C$0.01 (0.00%), bull C$0.03 (+200.00%), dependent on financing or clinical progress. Forecasts are model-based projections and not guarantees.

Final Thoughts

PHRX.CN stock is trading at C$0.01 on 19 Feb 2026 after a 33.33% intraday fall that highlights low liquidity and fragile investor confidence in Pharmadrug Inc. The Healthcare sector has underperformed year over year, and the company’s negative EPS (-0.01), negative book value per share (-0.01395) and tiny market cap (C$1,082,344) amplify downside risk for traders. Meyka AI’s forecast model projects C$0.01 near term, implying 0.00% upside from current levels, while our scenario targets span C$0.005 (bear) to C$0.03 (bull). Technicals show oversold conditions (RSI 33.39) but a strong ADX 51.66, so momentum favors continuation until a catalyst appears. Investors should weigh the company rating (C-, Strong Sell) alongside the Meyka AI grade (67.94 — B, HOLD) and watch for liquidity, financing updates, or clinical data. Remember forecasts and grades are model outputs and not investment advice; conduct your own due diligence before trading PHRX.CN stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.